Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for Clearance
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
HIV persistence in latently infected, resting CD4 + T cells is broadly considered a barrier to eradicate HIV. Activation of the provirus using latency-reversing agents (LRAs) followed by immune-mediated clearance to purge reservoirs has been touted as a promising therapeutic approach. Histone deacetylases (HDACs) and histone acetyltransferases (HATs) control the acetylation level of lysine residues in histones to regulate the gene transcription. Several clinical HDAC inhibitors had been examined as LRAs, which induced HIV activation in vitro and in vivo. Here we report the discovery of a series of selective and potent class I HDAC inhibitors based on aryl ketones as a zinc binding group, which reversed HIV latency using a Jurkat model of HIV latency in 2C4 cells. The SAR led to the discovery of a highly selective class I HDAC inhibitor 10 with excellent potency. HDACi 10 induces the HIV gag P24 protein in patient latent CD4 + T cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While O-amino anilides are treated as the golden standard for class I HDAC selectivity, Liu et al. [89] showed that Zn2+-binding can also occur by using novel ZBGs such as O-substituted benzamides (amide bond is transposed as opposed to anilides).”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [89]
In the citing paper
“In particular, compound 8 was HDAC3 selective (> 300-fold) over any other class I HDAC [89].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [89]
In the citing paper
“As seen in the examples of compounds 8–10 (Figure 16), benzamides with ortho substituents selectively targeted class I HDACs [88, 89].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [89]
Citations
Cites
Histone acetylation in chromatin structure and transcription
Grunstein, M. (1997) · Nature · doi:10.1038/38664 · Cited by 2,884
Siliciano, J. D., Kajdas, J., Finzi, D., Quinn, T. C., Chadwick, K., Margolick, J. B., Kovacs, C., Gange, S. J., & Siliciano, R. F. (2003) · Nature Medicine · doi:10.1038/nm880 · Cited by 1,703
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
Archin, N. M., Liberty, A. L., Kashuba, A. D., Choudhary, S. K., Kuruc, J. D., Crooks, A. M., Parker, D. C., Anderson, E. M., Kearney, M. F., Strain, M. C., et al. (2012) · Nature · doi:10.1038/nature11286 · Cited by 1,139
What's Up and Down with Histone Deacetylation and Transcription?
Pazin, M. J., & Kadonaga, J. T. (1997) · Cell · doi:10.1016/s0092-8674(00)80211-1 · Cited by 821
Rasmussen, T. A., Tolstrup, M., Brinkmann, C. R., Olesen, R., Erikstrup, C., Solomon, A., Winckelmann, A., Palmer, S., Dinarello, C., Buzon, M., et al. (2014) · The Lancet HIV · doi:10.1016/s2352-3018(14)70014-1 · Cited by 628
Deeks, S. G. (2012) · Nature · doi:10.1038/487439a · Cited by 604
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
Søgaard, O. S., Graversen, M. E., Leth, S., Olesen, R., Brinkmann, C. R., Nissen, S. K., Kjaer, A. S., Schleimann, M. H., Denton, P. W., Hey-Cunningham, W. J., et al. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005142 · Cited by 516
Ellis, L., Pan, Y., Smyth, G. K., George, D. J., McCormack, C., Williams-Truax, R., Mita, M., Beck, J., Burris, H., Ryan, G., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4262 · Cited by 297
Research works printed but not linked: 1
- Clausen D. J., Bioorg. Med. Chem. Lett.
Cited by
Strategies To Design Selective Histone Deacetylase Inhibitors
Melesina, J., Simoben, C. V., Praetorius, L., Bülbül, E. F., Robaa, D., & Sippl, W. (2021) · ChemMedChem · doi:10.1002/cmdc.202000934 · Cited by 118
Medicinal chemistry updates of novel HDACs inhibitors (2020 to present)
He, X., Hui, Z., Xu, L., Bai, R., Gao, Y., Wang, Z., Xie, T., & Ye, X.-Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113946 · Cited by 89
Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention
Ružić, D., Djoković, N., Srdić‐Rajić, T., Echeverría, C., Nikolic, K. M., & Santibanez, J. F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010209 · Cited by 70
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
Luo, Y., & Li, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228828 · Cited by 62
“Additionally, it as been reported that selectively inhibiting HDAC3 may help to discover some antiath sclerotic drugs [28,56].”
BackgroundThe Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs
Geurs, S., Clarisse, D., De Bosscher, K., & D’hooghe, M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00226 · Cited by 58
Metadata
- Authors
- Liu, J., Kelly, J., Yu, W., Clausen, D., Yu, Y., Kim, H., Duffy, J. L., Chung, C. C., Myers, R. W., Carroll, S., Klein, D. J., Fells, J., Holloway, M. K., Wu, J., Wu, G., Howell, B. J., Barnard, R. J. O., & Kozlowski, J. A.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
- Corresponding author
- Liu, Jian
- ORCID
- Venue
- ACS Medicinal Chemistry Letters
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-06-22
- Volume
- 11
- Issue
- 7
- Pages
- 1476-1483
- ISSN
- 1948-5875 (ISSN-L)
- PMC
- PMC7357218
- OpenAlex
- W3036218414
- Cited by
- 32
- References
- 21
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 5 · 2023: 7 · 2022: 4 · 2021: 8 · 2020: 2
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- ACS Medicinal Chemistry Letters (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Keywords
- class I HDAC inhibitors, HIV latency reversal, HIV-1, aromatic ketones, zinc binding, histone deacetylase, histone acetyltransferase, latency-reversing agents, HIV reservoir, CD4+ T cells, structure-activity relationship, Jurkat cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for Clearance. https://app.cochat.ai/papers/10.1021/acsmedchemlett.0c00302
- The paper
- Liu, J., Kelly, J., Yu, W., Clausen, D., Yu, Y., Kim, H., Duffy, J. L., Chung, C. C., Myers, R. W., Carroll, S., Klein, D. J., Fells, J., Holloway, M. K., Wu, J., Wu, G., Howell, B. J., Barnard, R. J. O., & Kozlowski, J. A. (2020). Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for Clearance. ACS Medicinal Chemistry Letters. https://doi.org/10.1021/acsmedchemlett.0c00302
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.